Nandini Piramal, Chairperson, Piramal Pharma Ltd
| Photo Credit:
cueapi
Companies need to “remain agile” to tackle external volatilities, and work with customers to manage costs, said Nandini Piramal, Chairperson, Piramal Pharma Ltd, as global uncertainties push up input costs for industries.“Work with your customers on pricing, …focus on improving efficiency...There has been volatility in things like solvents, transport…anything that’s plastic or petroleum-related,” Piramal told businessline, adding that they were in discussions to manage cost on a customer-basis.The company has started the year on a strong note, she said, as it posted a 17 per cent growth in revenues at ₹2,270 crore for the first quarter ended June 2026 (Q1 FY27). Its loss for the quarter under review reduced to ₹69 crore, from ₹82 crore, in the same period last year.All three businesses posted “mid-to-high teens revenue growth”, she said. The CDMO (contract development and manufacturing organisation) business was seeing more orders coming in with the resurgence in biotech funding.“We have seen with improved biopharma funding, we’ve seen increased demand at our overseas facilities. And I think that’s also helped us balance our both revenue and EBITDA growth. So, while we’ve increased…revenue by 19 per cent, EBITDA grew at 72 per cent. The complex hospital generics (CHG) segment saw traction in ex-US inhalation anesthesia markets, and the company was continuing with the integration of Kenalog. And the consumer healthcare business delivered robust growth, driven by power brands, and disciplined brand investments,” she said.The CDMO business saw a 19 per cent growth at ₹1,187 crore; the CHG segment posted 17 per cent growth at ₹743 crore; and consumer healthcare grew 15 per cent at ₹347 crore.“Encouraged by this momentum, we look forward to delivering sustained revenue growth and EBITDA expansion through FY27, while staying agile amid a dynamic external environment,” Piramal said. In the year ahead, she expected “all of them (businesses) to fire” to deliver “broad-based growth across the board”.Published on July 30, 2026
